Navigation Links
Curemark Moderates Autism Panel at Life Sciences Summit 2010
Date:10/11/2010

RYE, N.Y., Oct. 11 /PRNewswire/ -- Dr. Joan Fallon, founder and CEO of Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, moderated the neuroscience roundtable focused on autism at the Life Sciences Summit 2010, held September 22-23 in Hauppauge, New York.  

Sponsored by the State University of New York at Stony Brook, Brookhaven National Laboratories and Cold Spring Harbor Laboratories, the Life Sciences Summit focused on forging partnerships between biopharmaceutical companies and companies emerging from academia to accelerate biomedical solutions in areas including infectious disease, neuroscience, oncology and regenerative medicine.   In addition to serving as panel moderator, Dr. Fallon presented an update on Curemark's autism treatment CM-AT, currently in Phase III clinical trials, at the conference's Emerging Company and Innovator's Showcase.

"The Life Sciences Summit brought together researchers, scientists and representatives of companies working at the forefront of new medical developments, who shared and exchanged ideas in this very conducive forum.  The discussion at the Roundtable highlighted some of the latest research in identifying possible causes of autism as well promising new therapies," she said.  

Participating at the Roundtable entitled "Autism Spectrum Disorder: Recent Advances in the Development of Symptomatic Treatments" were Joseph Buxbaum, PhD, MSc, principal investigator, Laboratory of Molecular Neuropsychiatry, Mount Sinai School of Medicine; Deborah A. Pearson, PhD, professor, Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Texas Medical School at Houston; John Spiro, PhD, senior associate director for research, Simons Foundation; and Larry J.
'/>"/>

SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
2. James F. Szigethy Named Curemarks Director of New Product Development
3. Curemark to Present at BioPharm America™ 2010
4. Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Curemark Opens Autism Trials at New Jersey Site
6. Curemark Begins Autism Trials at Two More Sites
7. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
8. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
9. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
10. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
11. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... , July 24, 2014 Decision Resources Group ... the EU5 countries ( France , ... Spain and the ... of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) ... uptake of Relvar as a first-line LABA/ICS FDC in ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Calif., Nov. 17 Poniard Pharmaceuticals, Inc. (Nasdaq: ... randomized, controlled Phase 2 trial of picoplatin in patients ... indicated that picoplatin, given once every four weeks in ... has comparable efficacy to oxaliplatin, given in combination with ...
... , LAKE ZURICH, Ill., Nov. 17 ... improving blood collection, separation, safety and availability, announced today ... the Verax Platelet PGD® test as a quality control ... platelets prior to transfusion. Fenwal is the exclusive ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 2FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 4
(Date:7/24/2014)... 24, 2014 Just as fitness and ... consider their own financial and marketing strength to be ... campaigns to the next level by using the most ... IVR, Voice Broadcast, Call Tracking and SMS texting ... rate, text messages are quickly become integral in marketing ...
(Date:7/24/2014)... CarePoint Health is proud to ... oncology, Dr. Hitendra Upadhyaya, has joined our network, ... Upadhyaya to the community. Hundreds of highly skilled ... a comprehensive network of top doctors and practices ... specialties. This latest acquisition represents CarePoint Health’s commitment ...
(Date:7/24/2014)... of Medicine researchers may have found a way to ... that pre-treatment of neurons with the anti-aging protein Klotho ... toxic amyloid protein and glutamate. These findings currently appear ... , Alzheimer,s disease is the most frequent age-related dementia ... age 65 and older and more than 40 percent ...
(Date:7/24/2014)... -- Drinking caffeine may worsen the hot flashes and ... they go through menopause, new survey data suggests. ... limiting caffeine intake may be useful for those postmenopausal ... said researcher Dr. Stephanie Faubion, director of the Women,s ... But caffeine -- a stimulant found in coffee ...
(Date:7/24/2014)... Bonheur Children,s Hospital and the University of Tennessee Health ... a new drug shown to safely reduce the viral ... infected with respiratory syncytial virus (RSV). RSV is the ... young children in the United States and worldwide. ... Disease Specialist John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:RSV research breakthrough to help infected children 2
... contrast to normal cells, which only divide a finite number ... growth arrest or simply die, cancer cells never cease to ... have uncovered an important clue to one of the mechanisms ... April 22, 2011 issue of Molecular Cell , reveal ...
... -- A new poll finds that almost all parents of ... get exercise during each school day. However, one-third said their ... survey findings come at a time when U.S. schools continue ... Obesity is thought to affect one out of every six ...
... Monitoring Committee (DSMC) has determined that patients in a ... a standard chemotherapy regimen for advanced prostate cancer did ... patients on the same chemotherapy regimen who got a ... had advanced, hormone-refractory prostate cancer were given up to ...
... a high school athlete drops dead, the rare but ... For reasons that remain a mystery to scientists, some ... experience an unusual heart arrhythmia. With over-exertion, their hearts ... now, screening for the hard-to-detect syndrome has been prohibitively ...
... the worm is shedding light on a protein associated with ... a highly targeted way to treat them. University ... which is present in many cell types but whose exact ... protein controls key aspects of the movement, or secretion, of ...
... Even people who show a clear treatment ... like insomnia, sadness and decreased concentration, researchers at ... data from the largest study on the treatment ... working overall, missed these symptoms. If patients have ...
Cached Medicine News:Health News:A new ending to an old 'tail' 2Health News:A new ending to an old 'tail' 3Health News:U.S. Parents Want Kids More Active During School Day: Poll 2Health News:Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer 2Health News:Standing up for athletes at risk 2Health News:Worm studies shed light on human cancers 2Health News:Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 2Health News:Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 3
... The THERMOstar is a high performance temperature ... microplates. Temperature, shaking speed and incubation time ... the status parameters are displayed on the ... above and below the microplates provide uniform ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9 Broth...
An agent used for making solid microbiological media....
Medicine Products: